|Start Date / Time||March 20, 2017 at 12:15 PM|
|End Date / Time||March 20, 2017 at 1:15 PM|
|Location||1220 MRB III|
|Presenter Name||Paul Tesar, Ph.D.|
|Presentation Title||Chemical control of endogenous stem cells for treatment of myelin disorders|
|Status||This meeting has already occurred|
Oligodendrocyte progenitor cells (OPCs) are endogenous stem cells in the central nervous system that serve as the predominant source of myelinating oligodendrocytes. Oligodendrocyte loss or dysfunction can lead to significant motor and cognitive disability in patients due to myelination deficits. We have developed technologies that enable the rapid and robust generation of OPCs from pluripotent stem cells and via direct cell reprogramming technologies. These in vitro generated OPCs serve as a powerful platform to understand oligodendrocyte development and to discover therapeutic compounds for enhancing myelination. I will discuss our recent efforts to use high-throughput phenotypic screening of pluripotent stem cell-derived OPCs to uncover new aspects of oligodendrocyte biology.